Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.58 |
| ▸ | AXL | P30530 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31403147 | 0.83 | NPY5R (0.62) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL18876407 | 0.83 | NPY5R (0.62) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL77876 | 0.83 | MKNK1 (0.63) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL30516501 | 0.83 | MKNK1 (0.63) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL22497670 | 0.80 | MKNK1 (0.65) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL19826263 | 0.79 | CYP2A6 (0.54) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL12326414 | 0.79 | CYP2A6 (0.54) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL12260537 | 0.79 | CYP2A6 (0.54) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL12491570 | 0.79 | MKNK1 (0.60) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL11371958 | 0.79 | MKNK1 (0.62) | MKNK1MKNK2MEN1PSIP1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717459-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| EP-3768674-B1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S A S (FR) | 2024-01-03 | — | — | EP | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| US-20210002269-A1 | COMPOUNDS | STEP PHARMA S.A.S. (FR) | 2021-01-07 | — | — | US | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| EP-3543232-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | Step Pharma S.A.S. (FR) | 2019-09-25 | — | — | EP | disclosed |
| EP-3543232-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | Step Pharma S.A.S. (FR) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018136202-A2 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | CTPS1, CTPS2, TBXAS1 | MKNK1 2421/4885MKNK2 2359/4885MEN1 4301/4885 |
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | MKNK1 2655/4885MKNK2 2513/4885MEN1 320/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | MKNK1 2655/4885MKNK2 2513/4885MEN1 320/4885 |
| US-20210002269-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP19A1 | MKNK1 2645/4885MKNK2 2416/4885MEN1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.